Objective – To investigate how often referring physicians perform history taking and physical examination before PET/computed tomography (PET/CT) referral, and whether their absence influences clinical reasoning quality or diagnostic yield.  Methods – Patients undergoing PET/CT at a tertiary academic hospital were asked whether their referring physician had conducted history taking and physical examination before referral. Associations between omission of clinical assessment and clinical reasoning quality or PET/CT positivity (defined as PET/CT findings relevant to the clinical indication) were analyzed using multivariable regression.  Results – Among 288 patients (median...

BACKGROUND: Intra-abdominal desmoid tumours (IADT) can closely mimic gastrointestinal stromal tumours (GISTs), particularly in recurrence and metastases. However, differentiating these two diseases using radiological methods remains challenging. This study aimed to investigate the value of [ 18F]FAPI-42 PET/CT in differentiating IADT and GISTs compared to [ 18F]FDG PET/CT. METHODS: This study retrospectively included a total of 24 patients (12 patients with IADT and 12 patients with recurrent/metastatic GISTs) who underwent two separate PET/CT scans using [ 18F]FAPI-42 and [ 18F]FDG, respectively. The differences in tumour SUV max on...

Fibroblast activation protein-targeted radionuclide therapy (FAP-TRT) has emerged as a novel strategy for modulating the tumour microenvironment (TME) by selectively eradicating FAP-expressing cancer-associated fibroblasts (CAFs). Although preclinical studies have demonstrated promising results across various tumour models using diverse radiolabelled FAP inhibitors, clinical translation remains limited by modest efficacy, short tumour retention, and highly heterogeneousresponses. This review aims to provide an overview of recent advances in radiopharmaceutical design to enhance tumour targeting and prolong retention. Furthermore, we summarise early clinical findings and ongoing trials, while emphasising the potential translational...

BACKGROUND: Brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine (A-AVD) improves outcomes in advanced-stage classic Hodgkin lymphoma, but patients with a positive early interim PET have inferior prognosis. We evaluated whether very early [ 18F]fluorodeoxyglucose ([ 18F]FDG)-PET-guided treatment adaptation after one cycle of A-AVD improves activity while limiting exposure to intensive chemotherapy. METHODS: This single-arm, multicentre, phase 2 trial was conducted at 16 centres in seven countries (the Netherlands, Spain, Denmark, Belgium, Portugal, Slovakia, and Poland). Adults aged 18-60 years with previously untreated advanced-stage classic Hodgkin lymphoma, WHO...